March 19, 2020 10:04 AM EDT

Pfizer's JAK1 challenger to Dupixent shines in another PhIII, but safety issues still cast a shadow

Amber Tong

Pfizer is racking up ammunition for its full-on assault against Regeneron and Sanofi’s Dupixent franchise, with the latest topline win for an oral atopic dermatitis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer's JAK1 challenger to Dupixent shines in another PhIII, but safety issues still cast a shadow

Amber Tong

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Pfiz­er's JAK1 chal­lenger to Dupix­ent shines in an­oth­er PhI­II, but safe­ty is­sues still cast a shad­ow

Amber Tong

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Pfizer's JAK1 challenger to Dupixent shines in another PhIII, but safety issues still cast a shadow

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations